Lucid Diagnostics

LUCD · NASDAQ

$0.3519+$0.0091 (+2.65%)TodayMarket closed · Oct 21, 4:55 AM ET

Prev close $0.3428

Latest news

Press releaseSep 22, 7:55 AM ETPRNewswire
Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways
NewsAug 18, 8:13 AM ETPriya Nigam
Lucid Diagnostics Could Be 'High In The Queue' For Medicare Coverage Decision, Analyst Says
Press releaseAug 14, 8:00 AM ETPRNewswire
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results
NewsAug 13, 11:11 AM ET
Lucid Diagnostics Q2 2026 Earnings Call: Complete Transcript
Press releaseAug 13, 8:00 AM ETPRNewswire
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results
Press releaseAug 5, 8:46 AM ETPRNewswire
Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test
Press releaseAug 4, 8:30 AM ETPRNewswire
Lucid Diagnostics to Participate in Upcoming Investor Conferences
Press releaseJul 31, 8:30 AM ETPRNewswire
PAVmed to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 14, 2026
Press releaseJul 30, 8:30 AM ETPRNewswire
Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026
NewsJun 8, 11:25 AM ETPriya Nigam
Lucid Diagnostics Misses On Revenue, But 2026 Growth Outlook Lights Up Bull Case
Press releaseMay 15, 8:00 AM ETPRNewswire
PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results
Press releaseMay 14, 8:00 AM ETPRNewswire
Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results
NewsMay 14, 7:11 AM ET
Earnings Scheduled For May 14, 2026
Press releaseMay 1, 8:31 AM ETPRNewswire
PAVmed to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 15, 2026
Press releaseApr 30, 8:31 AM ETPRNewswire
Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026
Press releaseApr 24, 10:23 AM ETPRNewswire
Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock
Press releaseApr 23, 8:30 AM ETPRNewswire
Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock
Press releaseApr 9, 8:01 AM ETPRNewswire
Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference
Press releaseApr 2, 8:01 AM ETPRNewswire
PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio
Press releaseMar 30, 8:00 AM ETPRNewswire
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Press releaseMar 26, 8:00 AM ETPRNewswire
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
NewsMar 26, 7:11 AM ET
Earnings Scheduled For March 26, 2026
Press releaseMar 16, 9:01 AM ETPRNewswire
PAVmed to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 30, 2026
Press releaseMar 12, 9:01 AM ETPRNewswire
Lucid Diagnostics to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 26, 2026
NewsMar 6, 4:05 PM ET
12 Health Care Stocks Moving In Friday's After-Market Session
Press releaseFeb 4, 8:01 AM ETPRNewswire
PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities
NewsJan 22, 9:23 AM ETDylan Berman
What's Going On With PAVmed Shares Thursday?
NewsJan 21, 11:22 AM ETAkanksha Bakshi
Why Is PAVmed Stock Skyrocketing Wednesday?
Press releaseJan 21, 8:00 AM ETPRNewswire
Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard®
Press releaseDec 30, 9:01 AM ETPRNewswire
PAVmed Announces Reverse Stock Split
Press releaseDec 9, 8:01 AM ETPRNewswire
Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection
Press releaseNov 20, 8:15 AM ETPRNewswire
Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree
Press releaseNov 13, 8:15 AM ETPRNewswire
Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Press releaseNov 13, 8:00 AM ETPRNewswire
PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results
Press releaseNov 12, 8:00 AM ETPRNewswire
Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results
NewsNov 12, 6:11 AM ET
Earnings Scheduled For November 12, 2025
Press releaseAug 14, 8:00 AM ETPRNewswire
PAVmed Provides Business Update and Reports Second Quarter 2025 Financial Results
Press releaseAug 13, 8:00 AM ETPRNewswire
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results
NewsAug 13, 4:32 AM ET
Earnings Scheduled For August 13, 2025
NewsJun 2, 8:42 AM ETAvi Kapoor
SAIC, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
NewsJun 2, 8:07 AM ET
12 Health Care Stocks Moving In Monday's Pre-Market Session

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways

Lucid Diagnostics Could Be 'High In The Queue' For Medicare Coverage Decision, Analyst Says

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

Lucid Diagnostics Q2 2026 Earnings Call: Complete Transcript

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results

Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test

Lucid Diagnostics to Participate in Upcoming Investor Conferences

PAVmed to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 14, 2026

Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026

Lucid Diagnostics Misses On Revenue, But 2026 Growth Outlook Lights Up Bull Case

PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results

Earnings Scheduled For May 14, 2026

PAVmed to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 15, 2026

Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026

Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock

Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock

Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference

PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio

PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Earnings Scheduled For March 26, 2026

PAVmed to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 30, 2026

Lucid Diagnostics to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 26, 2026

12 Health Care Stocks Moving In Friday's After-Market Session

PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities

What's Going On With PAVmed Shares Thursday?

Why Is PAVmed Stock Skyrocketing Wednesday?

Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard®

PAVmed Announces Reverse Stock Split

Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection

Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree

Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results

Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results

Earnings Scheduled For November 12, 2025

PAVmed Provides Business Update and Reports Second Quarter 2025 Financial Results

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results

Earnings Scheduled For August 13, 2025

SAIC, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session

12 Health Care Stocks Moving In Monday's Pre-Market Session